GeneNews (TSX:GEN) is addressing the major issue in earlycancer screening - patient reluctance with inconvenient and intrusive screening methods - with a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early.
3D Signatures (TSX-V:DXD) which has developed proprietary software with the potential to analyze a patient’s chromosomal arrangement, or signature, is seeking collaborations to advance its TeloView platform in the areas of Hodgkin’s lymphoma, prostrate cancer, multiple myeloma and Alzheimer’s disease.
As head of healthcare research and as the senior biotechnology analyst with Maxim Group, Jason Kolbert has worked extensively in the healthcare sector. This includes pharma experience with Schering-Plough in Japan, as a fund manager and as an equity analyst for the past 20 years.
As an advisor and consultant with Cyrex Laboratories, a clinical immunology lab, Dr. Chad Larson holds a Doctor of Naturopathic Medicine degree from Southwest College of Naturopathic Medicine and a Doctor of Chiropractic degree from Southern California University of Health Sciences.
Wael Fayad, who moved into the executive suite of Enumeral (OTCQB:ENUM) as chairman, president and CEO at the end of September, plans to reboot the company in the near term through partnering and collaborations.
Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a neuroprotecter against brain cell death following acute neurologic injury, such as cardiac arrest.
With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in the first quarter next year with bladder cancer patients.
Clearside Biomedical (NASDAQ:CLSD) has priced an underwritten public offering of four million of its common shares at a price of $9 each for gross proceeds of $36-million.
3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).
ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X protein (HBx) and host cyclophilin A, with nanomolar potency.
RBC Capital Markets downgraded Concordia International (NASDAQ:CXRX; TSX:CXR) to “underperform” from “sector perform” and cut its price target to $1 from $2.50. The stock closed at $2.38 on Dec. 6.
3D Signatures (TSX-V:DXD) presented preliminary results of a collaborative initiative between the company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebecd, exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions.
BTIG downgraded iRhythm Technologies (NASDAQ:IRTC) to “neutral” from “buy,” noting that the shares recently surpassed BTIG’s price target of $28 but have fallen $1.25 at midday Dec.6 to $27.98.
Neovasc (NASDAQ:NVCN) provided an update on the clinical experience with its Tiara transcatheter mitral valve, sending the shares up 50% to $2.14 at midday Dec 6.
3D Signatures (TSX-V:DXD) has appointed Nigel Terrett to 3DS's business advisory board to provide the company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform.